Accommodating lens model continues trend of improved outcomes throughout implant evolution

Article

A fourth-generation version of an accommodating IOL (HD-100 crystalens, eyeonics) provides excellent uncorrected visual acuity (UCVA) at all distances without degrading contrast acuity, according to the results of an FDA multicenter clinical trial.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
A road sign with a brain on it in front of a highway. Image credit: ©Prime Lens – stock.adobe.com

Alzheimer disease retinopathy and brain-to-eye β-amyloid transport

Lynda Charters
October 4th 2024
Article

The research findings highlighted a new therapeutic avenue in ocular and neurodegenerative disease

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Image credit: ©Who is Danny – stock.adobe.com

What's missing in patient education?

Albert J. Augustin, MD
October 3rd 2024
Article

A different approach better serves patients with diabetic retinopathy

A patient undergoes an ocular exam in a clinic. Image credit: ©rocketclips – stock.adobe.com

Novaliq and Laboratoires Théa announce European Commission approval of ciclosporin 0.1% eye drops solution

Martin David Harp
October 2nd 2024
Article

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease

Images of eyes of patients with Fuchs endothelial corneal dystrophy

Novel therapies emerge for a progressive corneal disease

Kathryn A. Colby, MD, PhD
October 2nd 2024
Article

Current and future options for Fuchs endothelial corneal dystrophy

An AI-generated image of an eye with genetic material surrounding it. Image credit: ©Iftikhar alam – stock.adobe.com

The latest genetic research from this summer’s retina conferences

Hattie Hayes;Lynda Charters
October 2nd 2024
Article

Gene therapy was a major topic at the 2024 EURETINA and Retina Society meetings

© 2024 MJH Life Sciences

All rights reserved.